Pyogenic lung abscess in an infectious disease unit: a 20-year retrospective study.


Journal

Therapeutic advances in respiratory disease
ISSN: 1753-4666
Titre abrégé: Ther Adv Respir Dis
Pays: England
ID NLM: 101316317

Informations de publication

Date de publication:
Historique:
entrez: 8 6 2021
pubmed: 9 6 2021
medline: 16 2 2022
Statut: ppublish

Résumé

Pyogenic lung abscesses are rare and poorly described infections. This study aimed to describe their prognostic factors. We retrospectively included all patients hospitalized between 1 January 1998 and 1 June 2018, with an International Classification of Diseases, version 10 (IDC-10) diagnosis of pyogenic lung abscess, from the Diamm based medical records (Micro6, Nancy, France). Parasitic, fungal, or mycobacterial lung abscesses were excluded. A total of 64 patients were included. Abscesses were associated with immunosuppression in 28 patients, including HIV infection and immunosuppressive therapy for eight and 12 patients, respectively. Bacterial identification was obtained for 36 patients. Nine patients (14%) developed lung abscesses after hematogenous dissemination. They differed from bronchogenic abscesses by their younger age ( A duration of antibiotic treatment of less than 6 weeks and bronchogenic presentation were globally associated with poor outcome of pyogenic lung abscesses. These data should be considered when proposing guidelines for the care of pyogenic lung abscesses.

Sections du résumé

BACKGROUND
Pyogenic lung abscesses are rare and poorly described infections. This study aimed to describe their prognostic factors.
METHODS
We retrospectively included all patients hospitalized between 1 January 1998 and 1 June 2018, with an International Classification of Diseases, version 10 (IDC-10) diagnosis of pyogenic lung abscess, from the Diamm based medical records (Micro6, Nancy, France). Parasitic, fungal, or mycobacterial lung abscesses were excluded.
RESULTS
A total of 64 patients were included. Abscesses were associated with immunosuppression in 28 patients, including HIV infection and immunosuppressive therapy for eight and 12 patients, respectively. Bacterial identification was obtained for 36 patients. Nine patients (14%) developed lung abscesses after hematogenous dissemination. They differed from bronchogenic abscesses by their younger age (
CONCLUSION
A duration of antibiotic treatment of less than 6 weeks and bronchogenic presentation were globally associated with poor outcome of pyogenic lung abscesses. These data should be considered when proposing guidelines for the care of pyogenic lung abscesses.

Identifiants

pubmed: 34098822
doi: 10.1177/17534666211003012
pmc: PMC8191068
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17534666211003012

Références

Respirology. 2013 Oct;18(7):1095-100
pubmed: 23692607
Medicine (Baltimore). 1972 Nov;51(6):413-50
pubmed: 4564416
Clin Infect Dis. 2005 Apr 1;40(7):923-5
pubmed: 15824980
J Infect Chemother. 2018 May;24(5):376-382
pubmed: 29454633
Eur Respir J. 2019 Oct 1;54(3):
pubmed: 31248959
Curr Probl Surg. 1977 Nov;14(11):1-62
pubmed: 598215
South Med J. 1981 Mar;74(3):281-3
pubmed: 7221626
Ann Surg. 1983 Jun;197(6):755-62
pubmed: 6859981
Chest. 1999 Mar;115(3):746-50
pubmed: 10084487
Am J Med Sci. 1968 May;255:313-9
pubmed: 5650753
Expert Rev Respir Med. 2007 Aug;1(1):111-9
pubmed: 20477271
Clin Infect Dis. 2005 Apr 1;40(7):915-22
pubmed: 15824979
Intern Med. 1993 Apr;32(4):278-84
pubmed: 8358116
Clin Infect Dis. 1993 Jun;16 Suppl 4:S248-55
pubmed: 8324127
Eur Respir J. 1996 Oct;9(10):2031-5
pubmed: 8902463
Curr Ther Res Clin Exp. 1970 Mar;12(3):154-60
pubmed: 4985494
Ann Transl Med. 2015 Aug;3(13):183
pubmed: 26366400
Chest. 1974 Nov;66(5):536-40
pubmed: 4279163
Am Rev Respir Dis. 1974 May;109(5):510-8
pubmed: 4595941
Respiration. 2010;80(2):98-105
pubmed: 20389050
J Bras Pneumol. 2006 Mar-Apr;32(2):136-43
pubmed: 17273583
Arch Intern Med. 1990 Dec;150(12):2525-9
pubmed: 1978771
Am J Surg. 1985 Jul;150(1):97-101
pubmed: 4014575
Rev Pneumol Clin. 1993;49(3):137-41
pubmed: 8296141
Clin Microbiol Infect. 2004 Feb;10(2):163-70
pubmed: 14759242
Eur J Clin Microbiol Infect Dis. 2003 Mar;22(3):185-7
pubmed: 12649717
J Crit Care. 2015 Feb;30(1):40-8
pubmed: 25129577
Respir Med. 2002 Mar;96(3):178-85
pubmed: 11905552
Chest. 1974 Oct;66(4):348-51
pubmed: 4411851
WMJ. 2020 Mar;119(1):62-65
pubmed: 32348075
Expert Rev Anti Infect Ther. 2007 Jun;5(3):365-83
pubmed: 17547502
J Infect Dis. 1977 Mar;135 Suppl:S58-64
pubmed: 850092

Auteurs

Thomas Maitre (T)

Department of Infectious Diseases, AP-HP Hôpital Tenon, Sorbonne Université, Paris, France.

Vichita Ok (V)

Department of Parasitology and Mycology, AP-HP Hôpital Avicenne, Sorbonne Paris Nord, Bobigny, France.

Ruxandra Calin (R)

Department of Infectious Diseases, AP-HP Hôpital Tenon, Sorbonne Université, Paris, France.

Ludovic Lassel (L)

Department of Infectious Diseases, AP-HP Hôpital Tenon, Sorbonne Université, Paris, France.

Ana Canestri (A)

Department of Infectious Diseases, AP-HP Hôpital Tenon, Sorbonne Université, Paris, France.

Michel Denis (M)

Department of Infectious Diseases, AP-HP Hôpital Tenon, Sorbonne Université, Paris, France.

Mohammed Hamidi (M)

Department of Infectious Diseases, AP-HP Hôpital Tenon, Sorbonne Université, Paris, France.

Sebastian Tavolaro (S)

Department of Radiology, AP-HP Hôpital Tenon, Sorbonne Université, Paris, France.

Charlotte Verdet (C)

Department of Bacteriology, AP-HP Hôpitaux Universitaires de l'Est Parisien, Paris, France.

Antoine Parrot (A)

Department of Pneumology, AP-HP Hôpital Tenon, Sorbonne Université, Paris, France.

Jacques Cadranel (J)

Department of Pneumology, AP-HP Hôpital Tenon, Sorbonne Université, Paris, France.

Gilles Pialoux (G)

Department of Infectious Diseases, AP-HP Hôpital Tenon, Sorbonne Université, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH